956034-22-3

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 27407-11-0 3-bromo-4-fluorophenol 
• 956034-21-2 2-bromo-1-fluoro-4-((4-methoxybenzyl)oxy)benzene 
• 73183-34-3 bis(pinacol)diborane 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 1614246-79-5 4-(ethylsulfonyl)-2'-fluoro-5'-((4-methoxybenzyl)oxy)[1,1'-biphenyl]-2-carbonitrile 
• 1614246-82-0 4-(ethylsulfonyl)-2'-fluoro-5'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1-biphenyl]-2-carbonitrile 
• 1614245-77-0 5'-(7-ethyl-7H-imidazo[4,5-c]pyridazin-4-yl)-4-(ethylsulfonyl)-2'-fluoro-[1,1'-biphenyl]-2-carbonitrile 

Relevant academic research and scientific papers

Chemical Compounds

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Pharmaceutical compounds

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.